 JENA, Germany, Oct. 19, 2021 GLOBE NEWSWIRE -- InflaRx N.V. Nasdaq: IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that the German Ministry of Education and Research Bundesministerium für Bildung und Forschung or BMBF and the German Ministry of Health Bundesministerium für Gesundheit or BMG have notified InflaRx that the Company has been awarded a grant of up to EUR 43.7 million to support the development of vilobelimab for the treatment of severely ill, mechanically ventilated COVID-19 patients. 